Partner Article
Healthcare innovator to create 20 Northumberland jobs following inward manufacturing move
Healthcare firm Femeda has started its production of medical devices in Cramlington, which are used for the treatment of female urinary incontinence, after relocating its manufacturing lines from the United States to Northumberland a year ago.
The growing business, which already employs 12 people in the North East, will soon be recruiting for an additional 20 positions as the firm looks to scale considerably next year.
Needing to secure a scalable supply chain ahead of launching its new pelvic health product in early 2018, the business CEO Andrew Tasker cited the region as an ideal location to innovate in the sector.
He explained: “It’s great to be able to establish our in-house manufacturing capabilities and our ground-breaking technology in the North East.
“Our team are looking forward to launching our life-changing technology Pelviva® to women suffering from incontinence early next year.”
With 698 million women worldwide affected by incontinence, and a compound annual growth rate of 6%, the company has forecast significant market penetration for Pelviva® which uses reactive pulse technology to strengthen weak pelvic floor muscles, the underlying cause of urinary incontinence.
Andrew has over 30 years’ experience in consumer healthcare, medical devices and pharmaceuticals including working for Procter & Gamble, Boots, Bausch + Lomb and in MD roles at Pfizer Consumer Healthcare and Mentholatum.
His experience has seen him work across multiple health care sectors in the UK, Europe and Middle East Africa, launching multiple new technologies and innovations.
“We chose Cramlington for its strong heritage and reputation in healthcare and medical manufacturing,” added Andrew.
“We were quickly able to develop a highly experienced team to start our initial manufacturing. We plan to continue to expand the site as we initiate our global launch plan.”
Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →
Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.
Enjoy the read? Get Bdaily delivered.
Sign up to receive our daily bulletin, sent to your inbox, for free.
The real value of AI is the time it gives back
Breaking the magnetic pull of London
AI scepticism is healthy. Inaction isn't.
What does NPPF mean for site price and planning gain?
What new NPPF rules mean for landowners
The hidden cost squeezing Britain's economy
Teesside deserves more than cashback devolution
Construction must be built on commercial discipline
Devolution needs financial firepower to drive growth
The value of creating a stronger careers route
Apprenticeships: Invest in talent or keep chasing it
Are you ready for salary transparency?